Orum Therapeutics Pioneering Next-Generation Cancer Treatments with DAC Technology
Orum Therapeutics is emerging as a key player in the global new drug development landscape, driven by its innovative Degrader-Antibody Conjugate (DAC) platform – a next-generation technology for cancer treatment. The company is actively pursuing both technology transfer agreements and pipeline expansion, leveraging a novel approach that combines targeted protein degradation with antibody delivery.
Understanding DAC Technology
Orum’s DAC technology represents a new drug platform that merges Targeted Protein Degrading Agents (TPDs) with the precision of antibody-based drug delivery. Antibodies selectively target and deliver drugs to tumor cells, while degraders work within the cells to eliminate specific proteins. This approach is considered a significant advancement in cancer treatment, potentially overcoming the toxicity issues associated with traditional Antibody-Drug Conjugates (ADCs) and the systemic toxicity limitations of protein degraders. [Source: The Chosun Ilbo]
The PROTAb Platform and Competitive Advantages
At the heart of Orum Therapeutics’ DAC-based drugs is its proprietary PROTAb linker technology. This technology aims to ensure a stable connection between the TPD and the antibody, enhancing its effectiveness compared to existing ADC therapies. The PROTAb linker features a four-layer structure: antibody, linker, PROTAb linker, and payload. [Source: Korea BioMed]
DACs offer a competitive advantage by selectively delivering drugs to tumor cells using antibodies, potentially increasing the therapeutic index (TI). This targeted approach aims to maximize efficacy while minimizing off-target effects.
Strategic Partnerships and Financial Growth
Orum Therapeutics has secured significant partnerships with global pharmaceutical companies, demonstrating the value of its DAC technology.
- Bristol Myers Squibb (BMS): In 2023, Orum signed a technology transfer contract worth 260 billion won for its DAC candidate material ‘ORM-6151’ to BMS. BMS has secured global development rights and is currently conducting clinical development targeting blood cancer. [Source: The Chosun Ilbo]
- Vertex: Orum entered into a platform-based multi-target licensing agreement with Vertex, valued at 1.3 trillion won. Vertex can develop DAC treatments for up to three targets, with Orum Therapeutics eligible to receive milestone payments and royalties. [Source: The Chosun Ilbo]
Recently, Orum Therapeutics raised approximately 145 billion won through the issuance of convertible preferred stock (CPS), bolstering its capacity for research and development investment. [Source: The Chosun Ilbo]
Leadership and Innovation
Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum, emphasized the company’s commitment to precision engineering the next generation of DACs. The appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO) in January 2026, further strengthens Orum’s scientific leadership and innovation capabilities. Dr. May brings over 20 years of experience in oncology and immunology research, with a proven track record in advancing antibody drug conjugates (ADCs) and other therapeutic platforms. [Source: Orum Therapeutics News]
Orum’s History and Pioneering Role
Founded in 2016, Orum Therapeutics is recognized as the first Korean company to initiate a clinical trial utilizing DAC technology. Initially focused on antibody research, the company strategically shifted towards ADCs and ultimately pioneered the DAC approach, combining the strengths of both technologies. [Source: Korea BioMed]
Lee Seung-joo, CEO of Orum Therapeutics, stated in May 2024 that Orum can be considered the pioneer in DAC development, having steadily accumulated know-how in the field. [Source: Asiae.co.kr]